Corpus ID: 31121280

Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence

@article{Dooley2016BuprenorphinenaloxoneUI,
  title={Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence},
  author={J. Dooley and Lianne Gerber-Finn and I. Antone and J. Guilfoyle and Brittany Blakelock and Jazmyn Balfour-Boehm and W. Hopman and N. Jumah and L. Kelly},
  journal={Canadian Family Physician},
  year={2016},
  volume={62}
}
Objective To examine the maternal course and neonatal outcomes for women using buprenorphine-naloxone for opioid dependence in pregnancy. Design Retrospective cohort study comparing outcomes for the group of pregnant patients exposed to buprenorphine-naloxone with outcomes for those exposed to other narcotics and those not exposed to narcotics. Setting Northwestern Ontario obstetric program. Participants A total of 640 births in an 18-month period from July 1, 2013, to January 1, 2015. Main… Expand
Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
TLDR
Compared with buprenorphine monotherapy, the combined bupenorphine and naloxone product was an acceptable alternative pharmacologic treatment for opioid use disorder during pregnancy. Expand
Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.
TLDR
Pregnant women undergoing treatment for opioid use disorder with buprenorphine-naloxone do not experience significantly different pregnancy outcomes than women undergoing treatment with other forms of opioid agonist medication-assisted therapy. Expand
Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations
TLDR
This Investigational New Drug (IND) trial uniquely uses pragmatic features where feasible in order to maximize external validity, hence increasing the potential to inform clinical practice guidelines and address multiple knowledge gaps for treatment of this patient population. Expand
Maternal opioid use disorder and neonatal abstinence syndrome in northwest Ontario: a 7-year retrospective analysis.
  • J. Dooley, Gareth Ryan, +4 authors L. Kelly
  • Medicine
  • Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada
  • 2018
TLDR
Despite the continually increasing rates of opioid exposure in pregnancy, rates of NAS decreased annually and were substantially lower than those of the North West Local Health Integration Network and the regional LHIN. Expand
Using buprenorphine to treat neonatal abstinence syndrome: a quality improvement study
TLDR
To assess if treating neonatal abstinence syndrome with sublingual buprenorphine (SLB) would decrease the mean duration of therapy (DOT) and length of birth hospital stay (LOS), a quality improvement study using plan-do-study-act (PDSA) cycles was utilized. Expand
Management and monitoring of opioid use in pregnancy
TLDR
Buprenorphine is suggested as first‐line therapy for pregnant women with opioid use to replace the continued use of opioids or detoxification and to minimize risk of fetomaternal opioid exposure. Expand
Treating perinatal opioid use disorder in rural settings: Challenges and opportunities.
TLDR
Vermont and New Hampshire are predominantly rural states which have focused on expanding MAT access for pregnant women using two different approaches to integrating treatment with maternity care. Expand
No. 349-Substance Use in Pregnancy.
TLDR
This guideline is intended to increase the knowledge and comfort level of health care providers caring for pregnant women who have substance use disorders and to provide evidence-based recommendations for the management of this challenging clinical issue. Expand
Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance
TLDR
The literature review conducted using the RAND/University of California, Los Angeles Appropriateness Method project to obtain current evidence on treatment approaches for pregnant and parenting women with OUD and their infants and children found that NAS is an expected and manageable condition. Expand
Opioid use in pregnancy and parenting: An Indigenous-based, collaborative framework for Northwestern Ontario
TLDR
A critical need for a national strategy to address the effects of opioid use in pregnancy from a culturally safe, trauma-informed perspective that takes into account the health and well-being of the woman, her infant, her family and her community is identified. Expand
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
TLDR
Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. Expand
Methadone and Buprenorphine for the Management of Opioid Dependence in Pregnancy
TLDR
For a full remission of opioid addiction to be sustainable, both post-partum and across the lifespan, treatment providers must not rely solely on medication to treat their patients but should also utilize women-specific comprehensive treatment models that address the underlying multifaceted complexities of their patient’s lives. Expand
Buprenorphine and Naloxone Compared With Methadone Treatment in Pregnancy
TLDR
The authors found that 20% of their study population had filled opioid prescriptions during pregnancy, and the prevalence of opioid dependence had more than doubled during the time reviewed, mirroring what has been reported in the nonobstetric population. Expand
Opioid Detoxification in Pregnancy
TLDR
In selected patients, opioid detoxification can be accomplished safely during pregnancy, and there was no evidence of fetal distress during detoxification, no fetal death, and no delivery before 36 weeks. Expand
Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.
TLDR
Prenatal BMT versus MMT may improve neonatal outcomes, but bias may contribute to this protective association, and further evidence is needed to guide treatment choices. Expand
A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
TLDR
Preliminary findings suggest no significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy, however, further research should examine possible differences. Expand
Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario.
TLDR
In many patients, long-acting morphine preparations can be safely used and tapered in pregnancy, with a subsequent decrease in observed neonatal withdrawal symptoms, which is equivalent to those of the nonexposed pregnancies. Expand
Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications.
TLDR
Narcotic abuse during pregnancy is a considerable problem in First Nations communities in northwestern Ontario and community-based initiatives need to be developed to address this issue, and medical and nursing staff need to develop surveillance, assessment, and therapeutic responses. Expand
A Case Series of Buprenorphine/Naloxone Treatment in a Primary Care Practice
ABSTRACT Physicians’ adoption of buprenorphine/naloxone treatment is hindered by concerns over feasibility, cost, and lack of comfort treating patients with addiction. We examined the use ofExpand
Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study.
TLDR
Integrated care programs resulted in satisfactory obstetrical and neonatal outcomes for pregnant women on MMT and policies promoting maternal-newborn contact, rooming-in, and breastfeeding may help to decrease the severity of NAS and the need for pharmacological treatment of NAS. Expand
...
1
2
3
...